4-Bromo-2-fluoro-1-(trifluoromethoxy)benzene

We are 4-Bromo-2-fluoro-1-(trifluoromethoxy)benzene CAS:105529-58-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Bromo-2-fluoro-1-(trifluoromethoxy)benzene
CAS.NO:105529-58-6
Synonyms:1-Bromo-3-fluoro-4-(trifluoromethoxy)benzene; 
4-Bromo-2-Fluoro-1-(triFluoromethoxy)Benzene;
Molecular Formula:C7H3BrF4O
Molecular Weight:258.99600
 
Physical and Chemical Properties:
Density:1.724;
Boiling point:78oC;
Flash point:72.5oC;
Index of Refraction:1.459;
 
Specification:
Appearance:Colourless to yellow liquid
Purity:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

4-Bromo-2-fluoro-1-(trifluoromethoxy)benzene


Related News: Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Cloruro de 3-metilquinolina-8-sulfonilo CAS:74863-82-4 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Ácido 2-fluoro-5-nitrobenzoico CAS:7304-32-7 API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.3- (4-metil-1H-imidazol-1-il) -5- (trifluorometil) anilina CAS:641571-11-1 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
Triethoxysilane View Details
5-Nitrovanillin View Details
Benzyl 2-Naphthyl Ether View Details
3-piperidin-1-ylpropan-1-ol manufacturer 1-Bromopyrene manufacturer Ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate manufacturer N(Alpha)-Boc-L-2,3-Diaminopropionic Acid manufacturer 4-Fluoro-3-methylphenol manufacturer